Theory of change and strategic priorities of the world federation of haemophilia

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 29; no. 1; pp. 45 - 50
• Main Authors: Laliberté, Jennifer, Coffin, Donna, Haffar, Assad, Mekhuzla, Salome, Pierce, Glenn F., Flynn, Barry, Márquez, Carlos Safadi, Hermans, Cedric, Garrido, Cesar, Baumann, Alain
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.01.2023
• Subjects: Bleeding; bleeding disorders; diagnosis; Fallout; Gender; haemophilia; Health Personnel; Hemophilia; Hemophilia A - therapy; humanitarian aid; Humans; non‐governmental organization; theory of change; treatment; von Willebrand Diseases; treatment; bleeding disorders; humanitarian aid; haemophilia; diagnosis; non-governmental organization; theory of change
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.14673

The World Federation of Haemophilia (WFH) is a global network of national member organizations (NMOs) that advocate, collectively and individually, to improve lives of people with inherited bleeding disorders. The WFH vision of “Treatment for All” speaks to a future in which all people with an inherited bleeding disorder will have access to care, regardless of their gender or where they live. Over the last several years, initiatives including the WFH Humanitarian Aid program, the World Bleeding Disorders Registry, and Guidelines for the Management of Haemophilia and von Willebrand disease have significantly changed how the WFH and its partners work to improve and sustain care for people with bleeding disorders. Following an extensive consultation that included over 200 stakeholders from 70 countries, a Theory of Change was developed, and strategic priorities identified, to clearly define the WFH's intended impact and point of accountability to its stakeholders, and to determine how and through who those goals will be achieved. Both should help the WFH better support its NMOs and healthcare providers around the world in their efforts to improve access to diagnosis and care, as new therapies revolutionize the treatment landscape and the fallout of the global pandemic continues to challenge the ways in which we work and connect. Global collaboration of all stakeholders, based on their resources, objectives and skills, will be required to achieve these goals and to ensure more people have reliable access to safe treatment and care, regardless of their bleeding disorder, gender, or where they live.